Skip to main content
Premium Trial:

Request an Annual Quote

Oxford GlycoSciences' New CIO Will Spearhead Bioinformatics Charge


OXFORD, UK--Oxford GlycoSciences last month appointed Andrew Lyall to the position of chief information officer. Lyall formerly led research efforts in bioinformatics at Glaxo Wellcome as its head of advanced technology and informatics. At Glyco-Sciences he will be responsible for leading and expanding bioinformatics activities. Lyall holds a doctorate in bioinformatics from the University of Edinburgh and serves on a number of UK and international government and academic committees dealing with the emerging issues of bioinformatics and scientific computing.

GlycoSciences' CEO Michael Kranda remarked that "drug discovery, development, and commercialization are being transformed by new data- intensive technologies such as genomics and proteomics. But managing the data explosion and mining it for new therapeutic opportunities and diagnostics has resulted in a bottleneck which requires the development of advanced bioinformatics." Kranda added that he believes Lyall's expertise provides GlycoSciences with a competitive advantage as the company exploits its proteomics technology platform.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.